Lung Cancer in Nonsmoking Individuals
Lung cancer in nonsmoking individuals accounts for 15% to 20% of lung cancer cases worldwide. Among patients with lung cancer, nonsmoking individuals are more likely to have genomic alterations such as EGFR mutations or ALK gene rearrangements, and these patients have improved survival when treated with tyrosine kinase inhibitors compared with chemotherapy.
Authors
- Benjamin Solomon (ORCID: https://orcid.org/0000-0003-3059-5730)
- Cian Murphy (ORCID: https://orcid.org/0000-0003-1356-959X)
- Tej Pandya (ORCID: https://orcid.org/0000-0002-1816-1211)
- Charles Swanton
Institutions
- University College Hospital (GB)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- The Francis Crick Institute (GB)
- Royal London Hospital (GB)
- Cancer Research UK (GB)
- London Cancer (GB)
- Royal Marsden Hospital (GB)
- CRUK Lung Cancer Centre of Excellence (GB)
- University College London (GB)
Publication Details
- Journal
- JAMA
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1001/jama.2025.17695
- Citations
- 6
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 9.11